Close Menu
Surgical Times
    X (Twitter) Instagram TikTok
    Surgical Times
    • The Pulse
    • Under the Knife
    • Daily Chart
    • Cutting Edge
    • Doc Talk
    Wednesday • May 28, 2025
    Surgical Times
    Home»The Plastic Surgery Files

    FDA: Reports of BIA-SCC ‘Go Back Even Past the Last Decade’

    By Surgical TimesOctober 1, 2022


    “Dr. Nagel, you kind of answered in your presentation the FDA’s efforts towards breast implant safety registry’s tracking but maybe I could just ask a clarification question based on your presentation, with regards to the [FDA] update from September 8th on squamous cell carcinoma and B-cell lymphoma?

    One of the frequent questions that we get from patients and also surgeons is, ‘Was there an impetus for that warning?’

    Some of the citations that were given by the FDA showed the case reports over the last decade. And so was there any reason to the timing right now, or something that precipitated it?” — Dr. Mark W. Clemens, MD, MBA, FACS

    “Well thank you, Dr. Clemens, and you’re right about the chronicity of reports they go back even past the last decade.

    But our team continually evaluates post-market data and part of that looks at the current literature and information that forums such as this presents.

    We have a team, a breast implant team, that meets every week and we continually evaluate information on breast implants.

    You know, it’s accumulation of information that led to our looking further into this and we realize that although this safety signal may be relatively early compared to a lot of the other signals that are out there, it certainly warranted further investigation, as we’re doing now.

    One thing leads to another sometimes and it wasn’t just the squamous cell carcinomas.

    As we started to look further into the data, we realized that there are all sorts of other so-called various lymphomas that are not the BIA-ALCL.

    They’re not even all B-Cells and there are various T-Cell lymphomas so it’s a growing and evolving body of data that led us to realize that this is time for at least the initial communication and more to follow.” — Dr. Steven Nagel, MD, FACS, US FDA



    [October 1, 2022, Houston, Texas, 8th International Breast Surgery Workshop & 4th World Consensus Conference on BIA-ALCL. Dr. Mark W. Clemens, MD, MBA, FACS is an Associate Professor in plastic surgery, University of Texas MD Anderson Cancer Center. Dr. Steven Nagel, MD, FACS is the Medical Officer, Office of Surgical and Infection Control Devices, for the U.S. FDA]

    BIA-SCC U.S. FDA
    Top News

    America’s Best Plastic Surgeons Announced

    Breast Implant Statistics

    Superior Court Strikes SLAPP Suit Brought by Surgery Center

    Do I Need to Replace My Implants Every 10 Years?

    Top Exclusives

    Death Prompts Public Dig Into Surgeon’s Past: Jessica Jones’s ‘Justice for Hillary’

    Infrared Saunas a ‘Catalyst’ for ‘Breast Implant Illness’ Healthcare CEO Says

    FDA Analysis: Top 10 Symptoms of BII, Reported Rate of Improvement Post Explant

    Surgeon Counters Claims he Botched Woman’s Nose, Deletes Bad Reviews

    Objective. Independent. Informative. Public interest reporting on the practice of plastic surgery not affiliated with or funded by any surgeon, device manufacturer, or practice.

    Instagram X (Twitter) TikTok Facebook YouTube Pinterest
    • Terms
    • Contact
    • Privacy

    © 2025 Surgical Times. All Rights Reserved.

    • Best Of
    • Brazilian Butt Lift Surgery
    • Breast Implants
    • Breast Implant Illness
    • Celebrities
    • Death
    • Ethics
    • Exclusive
    • Florida
    • Uplifting
    • Legal
    • Marketing
    • Mold
    • Money
    • Podcasts
    • Safety
    • Social
    • Statistics
    • Studies
    • Türkiye
    • U.S.
    • U.S. FDA
    • World
    • Press Releases

    Type above and press Enter to search. Press Esc to cancel.